natgillin/translations-raw huggingface dataset:
For the 14, 28, 56, 84 and 98 tablets pack sizes, you can check the day on which you last took a tablet of Glidipion by referring to the calendar printed on the blister. 
Pri pakiranih s 14, 28, 56, 84 in 98 tabletami lahko dan, ko ste vzeli zadnjo tableto zdravila Glidipion, preverite na koledarčku, ki je natisnjen na pretisnem omotu.
5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials. 
O edemih so poročali pri 6 do 9 % bolnikov, ki so v kontroliranih kliničnih preskušanjih prejemali pioglitazon več kot eno leto.
Although in very rare cases fatal outcome has been reported, causal relationship has not been established. 
V zelo redkih primerih so bolniki umrli, vendar vzročna povezanost ni ugotovljena.
If ALT levels are increased to 3 X upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible. 
Če se raven ALT med zdravljenjem s pioglitazonom zviša na 3-kratno zgornjo normalno mejo, je treba čim prej znova določiti raven jetrnih encimov.
This medicine does not require any special storage precautions. 
Za shranjevanje zdravila niso potrebni posebni previdnostni ukrepi.
- if you have heart failure or have had heart failure in the past. 
- če imate ali ste kdaj v preteklosti imeli srčno popuščanje.
In patients who fail to show an adequate response, pioglitazone should be discontinued. 
Pri bolnikih, pri katerih ni ustreznega odziva, je treba zdravljenje s pioglitazonom končati.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2-5%. 
Delež edemov v skupinah s primerjalnim zdravilom (sulfonilsečnina, metformin) je bil od 2 do 5 %.
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. 
Po izključitvi bolnikov, pri katerih je izpostavljenost raziskovanemu zdravilu ob postavitvi diagnoze raka sečnega mehurja trajala manj kot eno leto, je bilo med prejemniki pioglitazona 7 primerov (0,06 %) in v kontrolnih skupinah 2 primera (0,02 %).
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree. 
To poteka predvsem preko citokroma P450 2C8, v manjši meri pa so lahko vpletene še druge izooblike.
No dose adjustment is necessary for elderly patients (see section 5.2). 
Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavje 5.2).
In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months. 
V preskušanju, kontroliranem s placebom, so bolnike z nezadostno urejenostjo glikemije kljub trimesečni optimizaciji insulina randomizirali na pioglitazon ali placebo za 12 mesecev.
It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus, when metformin is not suitable or has failed to work adequately. 
Je zdravilo za zdravljenje sladkorne bolezni tipa 2 (ki ni odvisna od insulina), ko metformin ni primeren ali ne deluje na ustrezen način.
Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity. 
Podobne spremembe v porazdelitvi telesnega maščevja med zdravljenjem s pioglitazonom je spremljalo izboljšanje občutljivosti za insulin.
As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation. 
Zaradi povečanega delovanja insulina lahko zdravljenje s pioglitazonom pri bolnicah s sindromom policističnih jajčnikov povzroči obnovitev ovulacije.
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin 
Kombinacija z metformino m s sulfonilsečnino z metformino m in sulfonilsečnino z insulinom
Monitoring of liver function 
Nadzor delovanja jeter
In animals, only a small amount of unchanged pioglitazone can be detected in either urine or faeces. 
Pri živalih se v urini ali blatu pojavi le malo nespremenjenega pioglitazona.
A 24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder. 
24-mesecev študija mehanizma pri podganjih samcih je pokazala, da uporaba pioglitazona poveča incidenco hiperplastičnih sprememb v sečnem mehurju.
This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study. 
V tej študiji so zabeležili več srčnega popuščanja, vendar pa to v študiji ni povečalo umrljivosti.
14 tablets 28 tablets 30 tablets 50 tablets 56 tablets 84 tablets 90 tablets 98 tablets 100 tablets 
14 tablet 28 tablet 30 tablet 50 tablet 56 tablet 84 tablet 90 tablet 98 tablet 100 tablet
In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline. 
V enoletnih kliničnih preskušanjih je pioglitazon dosledno statistično značilno znižal razmerje albumin/kreatinin v primerjavi z izhodiščnimi vrednostmi.
Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment (risks include age, smoking history, exposure to some occupational or chemotherapy agents e.g. cyclophosphamide or prior radiation treatment in the pelvic region). 
Dejavnike tveganja za raka sečnega mehurja je treba oceniti pred začetkom zdravljenja s pioglitazonom (med njimi so starost, anamneza kajenja, poklicna izpostavljenost nekaterim snovem ali kemoterapiji, npr. ciklofosfamidu, ali predhodno obsevanje medeničnega predela).
Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. 
Po peroralni uporabi se pioglitazon hitro absorbira; vrh koncentracije nespremenjenega pioglitazona v plazmi je po navadi dosežen v 2 urah po uporabi.
Your doctor will ask you to have blood tests periodically during treatment with Glidipion. 
Zdravnik vam bo naročil, da med zdravljenjem z zdravilom Glidipion redno opravljate preiskave krvi.
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from 10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029). 
V metaanalizi kontroliranih kliničnih preskušanj so o raku sečnega mehurja poročali pogosteje pri prejemnikih pioglitazona (19 primerov med 12.506 bolniki, 0,15 %) kot v kontrolnih skupinah (7 primerov med 10.212 bolniki, 0,07 %), razmerje ogroženosti = 2,64 (95 % IZ: 1,11-6,31, p = 0,029).
• The risk of heart failure and relevant risk minimisation advice. 
• Tveganju za srčno popuščanje in ustreznim nasvetom za zmanjšanje tega tveganja.
Environmental Risk Assessment: no environmental impact is anticipated from the clinical use of pioglitazone. 
Ocena tveganja za okolje: v zvezi s klinično uporabo pioglitazona ni pričakovati vpliva na okolje.
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. 
- pri odraslih bolnikih (zlasti bolnikih s čezmerno telesno maso), ki imajo bolezen nezadostno urejeno z dieto in telesno dejavnostjo in za katere metformin ni primeren zaradi kontraindikacij ali neprenašanja.
Symptoms are unusual shortness of breath or rapid increase in weight or localised swelling (oedema). 
Simptomi so nenavadno kratka sapa, hitro povečanje telesne mase ali omejeno otekanje (edemi).
To be eligible patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. 
Da bi bolniki ustrezali merilom, so morali imeti v anamnezi eno ali več od naslednjega: miokardni infarkt, možgansko kap, perkutan poseg na srcu ali obvodno operacijo koronarnih arterij, akutni koronarni sindrom, bolezen koronarnih arterij ali obstruktivno bolezen perifernih arterij.
Very common (may affect more than 1 in 10 people) - decreased blood sugar (hypoglycaemia) 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov) - znižanje krvnega sladkorja (hipoglikemija)
You can usually continue to take other medicines whilst you are being treated with Glidipion. 
Po navadi lahko med jemanjem zdravila Glidipion še naprej jemljete tudi druga zdravila.
If jaundice is observed, the medicinal product should be discontinued. 
Če se pojavi zlatenica, je treba uporabo tega zdravila prekiniti.
OTHER (FOR CALENDARISED PACKS SIZES OF 14, 28, 56, 84 AND 98 TABLETS ONLY) 
DRUGO (ZA KOLEDARSKA PAKIRANJA - SAMO ZA VELIKOSTI 14, 28, 56, 84 IN 98 TABLET)
- hypersensitivity to the active substance or to any of the excipients - cardiac failure or history of cardiac failure (NYHA stages I to IV) - hepatic impairment - diabetic ketoacidosis - current bladder cancer or a history of bladder cancer - uninvestigated macroscopic haematuria. 
- preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov - srčno popuščanje ali anamneza srčnega popuščanja (razredi od I do IV po NYHA) - okvara jeter - diabetična ketoacidoza - rak sečnega mehurja trenutno ali v anamnezi - neraziskana makroskopska hematurija.
Other medicines and Glidipion 
Drugiha zdravila in zdravilo Glidipion
- Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4). 
- Pioglitazon je indiciran tudi za kombinirano zdravljenje z insulinom pri odraslih bolnikih s sladkorno boleznijo tipa 2, ki glikemije nimajo zadostno urejene z insulinom, metformin pa zanje ni primeren zaradi kontraindikacij ali neprenašanja (glejte poglavje 4.4).
If you are following a diabetic diet, you should continue with this while you are taking Glidipion. 
Če se držite diabetične diete, dieto nadaljujte tudi med jemanjem zdravila Glidipion.
• The risk of bladder cancer and relevant risk minimisation advice. 
• Tveganju za raka sečnega mehurja in ustreznim nasvetom za zmanjšanje tega tveganja.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. 
Izračunana incidenca zlomov je bila 1,9 zloma na 100 bolnik-let pri ženskah, zdravljenih s pioglitazonom, in 1,1 zloma na 100 bolnik-let pri ženskah, zdravljenih s primerjalnim zdravilom.
A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA1c ≥ 8.0% after the first six months of therapy). 
Klinično preskušanje pioglitazona v primerjavi z gliklazidom kot monoterapijo so podaljšali na dve leti za oceno časa do neuspeha zdravljenja (ta je bil opredeljen kot pojav HbA1c ≥ 8.0 % po prvih šestih mesecih zdravljenja).
Since there is a potential for an increase in dose-related adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. 
Ker obstaja možnost povečanja od odmerka odvisnih neželenih učinkov, utegne biti med sočasno uporabo z gemfibrozilom potrebno zmanjšanje odmerka pioglitazona.
Any macroscopic haematuria should be investigated before starting pioglitazone therapy. 
Vsako makroskopsko hematurijo je treba raziskati pred začetkom zdravljenja s pioglitazonom.
However, the incidences of oedema, weight gain and heart failure were increased. 
Toda incidence edemov, povečanja telesne mase in srčnega popuščanja so bile večje.
Your doctor will check whether Glidipion is working 3 to 6 months after you start taking it. 
Vaš zdravnik bo od 3 do 6 mesecev potem, ko boste začeli jemati zdravilo Glidipion, preveril, ali zdravilo pri vas deluje.
If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. 
Če ste vzeli večji odmerek zdravila Glidipion, kot bi smeli Če pomotoma vzamete preveč tablet, ali če vaše zdravilo vzame kdo drug ali otrok, se nemudoma posvetujte z zdravnikom ali farmacevtom.
Glidipion can be taken with or without food. 
Zdravilo Glidipion lahko vzamete s hrano ali brez nje.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. 
Študije pri človeku ne kažejo indukcije glavnih inducibilnih izoencimov citokroma P450 1A, 2C8/9 in 3A4.
However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these. 
A pri nekaterih zdravilih je še posebej verjetno, da vplivajo na količino sladkorja v krvi: - gemfibrozil (uporablja se za znižanje holesterola), - rifampicin (uporablja se za zdravljenje tuberkuloze in drugih okužb).
Before you start taking Glidipion you will have a blood sample taken to check your liver function. 
Pred začetkom jemanja zdravila Glidipion boste morali opraviti preiskavo krvi za kontrolo delovanja jeter.
Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). 
Zdravnika morate čim prej obvestiti, če se vam pojavijo znaki srčnega popuščanja, npr. nenavadno kratka sapa, hitro povečanje telesne mase ali omejeno otekanje (edemi).
If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. 
Če se pojavijo simptomi, ki nakazujejo moteno delovanje jeter - med takšnimi so lahko nepojasnjena navzea, bruhanje, bolečine v trebuhu, utrujenost, anoreksija in/ali temen urin - je treba preveriti jetrne encime.
Close monitoring of glycaemic control should be considered (see section 4.4). 
Potrebno je natančno spremljanje urejenosti glikemije (glejte poglavje 4.4).
- The other ingredients are lactose monohydrate, hydroxypropylcellulose, carmellose calcium and magnesium stearate. 
- Pomožne snovi so: laktoza monohidrat, hidroksipropilceluloza, kalcijev karmelozat in magnezijev stearat.
Intrinsic clearance is therefore reduced, coupled with a higher unbound fraction of pioglitazone. 
Intrinzični očistek je zato manjši, obenem je delež nevezanega pioglitazona večji.
Dietary acidification significantly decreased but did not abolish the incidence of tumours. 
Prehransko zakisanje je incidenco tumorjev bistveno zmanjšalo, ni pa je odpravilo.
Pioglitazone effects may be mediated by a reduction of insulin resistance. 
Mehanizem učinkov pioglitazona je lahko zmanjšanje odpornosti proti insulinu.
Immune System Disorders 
Bolezni imunskega sistema
Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. 
Kot kaže, sočasna uporaba pioglitazona in sulfonilsečnin ne vpliva na farmakokinetiko sulfonilsečnine.
Following initiation of therapy with pioglitazone, it is recommended that liver enzymes be monitored periodically based on clinical judgement. 
Po začetku zdravljenja s pioglitazonom je priporočljivo jetrne encime kontrolirati redno po klinični presoji.
Glidipion contains pioglitazone. 
Zdravilo Glidipion vsebuje pioglitazon.
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group. 
Prejemnikom pioglitazona se je HbA1c v povprečju znižal za 0,45 % v primerjavi s tistimi, ki so nadaljevali zdravljenje samo z insulinom, in odmerek insulina se je v skupini zdravljenih s pioglitazonom zmanjšal.
Steady state pharmacokinetics are similar in patients age 65 and over and young subjects. 
Farmakokinetika v stanju dinamičnega ravnovesja je pri bolnikih, starih 65 let ali več, podobna kot pri mlajših preiskovancih.
Common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence (wind) 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) - glavobol - omotica - bolečine v sklepih - impotenca - bolečine v hrbtu - kratka sapa - rahlo zmanjšanje števila rdečih krvnih celic - napenjanje (vetrovi)
2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments. 
O motnjah vida so poročali predvsem zgodaj med zdravljenjem, povezane pa so s spremembami vrednosti glukoze v krvi, in sicer zaradi začasnih sprememb nabreklosti (turgidnosti) in refrakcijskega indeksa leče, kakršne se pojavljajo tudi pri drugih zdravilih za znižanje glikemije.
Frequency of adverse reactions of pioglitazone by treatment regimen 
Pogostnost neželenih učinkov pioglitazona po shemi zdravljenja
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics. 
Vpliv pioglitazona (45 mg v monoterapiji v primerjavi s placebom) so raziskali v majhnem, 18-tedenskem preskušanju pri sladkornih bolnikih tipa 2.
What Glidipion is and what it is used for What you need to know before you take Glidipion How to take Glidipion 
Kaj je zdravilo Glidipion in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Glidipion Kako jemati zdravilo Glidipion Možni neželeni učinki
In clinical trials with pioglitazone there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention. 
V kliničnih preskušanjih s pioglitazonom so opažali z odmerkom povezano povečanje telesne mase, ki je lahko posledica nabiranja maščob in je v nekaterih primerih povezano z zastajanjem tekočine.
Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5). 
V poštev pridejo prilagoditev odmerka pioglitazona v okviru priporočenega odmerjanja ali spremembe zdravljenja sladkorne bolezni (glejte poglavje 4.5).
as monotherapy 
Kot monoterapija
Reproductive system and breast disorders erectile dysfunction common 
Motnje reprodukcije in dojk erektilna disfunkcija pogosto
Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. 
Urejenost glikemije na tešče in po obrokih se pri bolnikih s sladkorno boleznijo tipa 2 izboljša.
It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes. 
Zato je bolnikom, zdravljenim s pioglitazonom, priporočljivo redno kontrolirati jetrne encime.
In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4). 
Zaradi tveganj, ki so povezana z dolgotrajnim zdravljenjem, morajo zdravniki na nadaljnjih rutinskih pregledih preverjati, da je korist pioglitazona še prisotna (glejte poglavje 4.4).
Glidipion helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces. 
Zdravilo Glidipion pri sladkorni bolezni tipa 2 pomaga obvladati koncentracijo krvnega sladkorja, ker telesu pomaga bolje izrabiti insulin.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJE
In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. 
V kliničnih preskušanjih s pioglitazonom je bila incidenca zvišanj ALT na več kot trikratno zgornjo normalno mejo enaka kot pri placebu, a manjša kot v primerjalnih skupinah z metforminom ali sulfonilsečnino.
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin. 
V študiji izidov pri bolnikih z obstoječo hujšo makrovaskularno boleznijo je bila incidenca resnega srčnega popuščanja po dodatku zdravljenju, ki je vključevalo insulin, 1,6 % večja s pioglitazonom kot s placebom.
Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance. 
Ugotovljeno je, da zdravljenje s pioglitazonom zmanjša sproščanje glukoze iz jeter in poveča periferno odstranjevanje glukoze v primeru odpornosti proti insulinu.
Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. 
Tako insulin kot pioglitazon sta povezana z zastajanjem tekočine, zato lahko njuna sočasna uporaba poveča tveganje edemov.
The Prescriber Guide should highlight the following: 
V vodniku za predpisovanje mora biti poseben poudarek namenjen:
Blood and lymphatic system disorders anaemia common 
Bolezni krvi in limfatičnega sistema anemija pogosto
In patients with renal impairment, plasma concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. 
Pri bolnikih z okvaro ledvic je koncentracija pioglitazona in njegovih presnovkov v plazmi manjša kot pri preiskovancih z normalnim delovanjem ledvic, a peroralni očistek matične snovi je podoben.
Glidipion tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. 
Tablete Glidipion vsebujejo laktoza monohidrat, zato bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze, ne smejo jemati tega zdravila.
In comparator groups, addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg. 
V primerjalnih skupinah je dodatek sulfonilsečnine metforminu povzročil povprečno povečanje telesne mase za 1,3 kg in dodatek metformina sulfonilsečnini povprečno zmanjšanje telesne mase za 1,0 kg.
It is not known whether pioglitazone is secreted in human milk. 
Ni znano, ali se pioglitazon pri človeku izloča v materinem mleku.
Mean levels of liver enzymes decreased with treatment with pioglitazone. 
Povprečna raven jetrnih encimov se je med zdravljenjem s pioglitazonom znižala.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. 
Nekaterim bolnikom z dolgotrajno sladkorno boleznijo tipa 2 in boleznijo srca ali predhodno možgansko kapjo, ki so prejemali pioglitazon in insulin, se je pojavilo srčno popuščanje.
In combination with insulin, the current insulin dose can be continued upon initiation of pioglitazone therapy. 
V kombinaciji z insulinom je mogoče insulin po uvedbi zdravljenja s pioglitazonom nadaljevati v dotlej uporabljanem odmerku.
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 ml/min) (see section 5.2). 
Bolnikom z okvarjenim delovanjem ledvic (očistek kreatinina > 4 ml/min) odmerka ni treba prilagoditi (glejte poglavje 5.2).
There is no induction of the main inducible P450 isoenzymes 1A, 2C8/9, and 3A4 in man. 
Pri človeku ni indukcije glavnih inducibilnih izoencimov P450 1A, 2C8/9 in 3A4.
In combination trials pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg. 
V kombiniranih preskušanjih zdravljenja je pioglitazon, dodan metforminu, povzročil povprečno povečanje telesne mase v enem letu za 1,5 kg, dodan sulfonilsečnini pa za 2,8 kg.